Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China

Reuters

07/04

Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China

Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2548336219"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2548336219\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2548336219?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-04 08:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2548336219","market":"us","top_or_hot":-1,"title":"Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBrii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-04 08:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0077","symbol_name":"质押式回购","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nNDL7yT8W1:1","article_id":"2548336219","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2548336219","pubTimestamp":1751589021,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or leg","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600380":"健康元","BK0077":"质押式回购","BK0046":"生物疫苗","BK0028":"国家队","BK0239":"医药制造","02137":"腾盛博药-B","BK1161":"生物科技","BK0114":"健康中国","BK1587":"次新股","BK1574":"生物医药B类股","BK0188":"融资融券"},"translate_title":"Brii Biosciences Ltd.与健康元集团合作，在大中华区推进BRII-693治疗抗生素耐药性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600380":0.9,"02137":0.9},"content_text":"Brii Biosciences Ltd. Partners with Joincare Group to Advance BRII-693 for Antimicrobial Resistance in Greater China\n    \n\n        Brii Biosciences Ltd. has announced a new licensing agreement with Joincare Group for the development and commercialization of BRII-693, a novel hospital antibiotic, in the Greater China region. Under this agreement, Joincare Group will take charge of clinical development, regulatory approval, and commercialization. The collaboration is aimed at addressing the growing threat of antimicrobial resistance, with early data indicating BRII-693's potential as a best-in-class therapy. Brii Biosciences will retain rights outside Greater China and will continue investing in other projects. The results of the clinical trials for BRII-693 have not yet been presented and will be shared in future communications.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Brii Biosciences Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN24169) on July 04, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}